Moody's Ratings (Moody's) has completed a periodic review of the ratings of Insight Enterprises, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 April 2025 in which we reassessed the appropriateness of the ratings in the co...
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the sec...
A director at Snap Inc sold/gave away 1,301,240 shares at 0.000USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent...
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March: TD Cowen 45th Annual Healthcare Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesd...
CHANDLER, Ariz.--(BUSINESS WIRE)-- Insight Enterprises, Inc. (Nasdaq: NSIT) (the “Company”) today announced that it is scheduled to participate in the following upcoming investor conference: Raymond James 46th Annual Institutional Investors Conference March 4, 2025, 8:05 AM ET Participants: James Morgado, CFO The Insight presentation will be broadcast live over the Internet at where you can also view other recent webcasts, downloadable slide presentations and other investor information. About Insight Insight Enterprises is a leading Solutions Integrator that helps clients solve techno...
CHANDLER, Ariz.--(BUSINESS WIRE)-- (NASDAQ: NSIT) today unveiled its enhanced (Flex) program, offering organizations cost-saving and simplified Device-as-a-Service (DaaS) solutions. Flex improves employee experience (EX) by getting the right devices to the right users when they need them to minimize downtime and increase productivity. With automation, proactive communications, a simplified e-commerce experience, and near-real-time intelligent data, organizations gain visibility for better device management. This press release features multimedia. View the full release here: Amid economic un...
Our target declines to $16 from $17 owing to lower estimates, partially offset by a higher valuation owing to growing long-term revenue potential after SNAP’s advertiser base doubled in 2024, while Snapchat+ continues to layer in a more predictable subscription revenue stream.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.